Temat: "Hepatitis C, Chronic" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.
Autorzy :: Rauff B; Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, Australia.; Institute of Biomedical and Allied Health Sciences (IBAHS), University of Health Sciences (UHS), Lahore, Pakistan.
Amar A; Department of Human Genetics and Molecular Biology, University of Health Sciences (UHS), Lahore, Pakistan.
Chudhary SA; Institute of Biomedical and Allied Health Sciences (IBAHS), University of Health Sciences (UHS), Lahore, Pakistan.
Mahmood S; Institute of Biomedical and Allied Health Sciences (IBAHS), University of Health Sciences (UHS), Lahore, Pakistan.
Tayyab GUN; Lahore General Hospital, Lahore, Pakistan.
Hanif R; Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan. .; Pokaż więcej
Źródło :: Archives of virology [Arch Virol] 2021 Apr; Vol. 166 (4), pp. 1047-1056. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :: Journal Article
MeSH Terms :: Genetic Predisposition to Disease/*genetics
Hepatitis C, Chronic/*genetics
Interferons/*genetics
Interleukins/*genetics
Liver Cirrhosis/*genetics
Adult ; Female ; Genetic Association Studies ; Genotype ; Hepacivirus/genetics ; Hepacivirus/isolation & purification ; Hepatitis C, Chronic/epidemiology ; Hepatitis C, Chronic/pathology ; Humans ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/pathology ; Male ; Middle Aged ; Pakistan/epidemiology ; Polymorphism, Single Nucleotide
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
Autorzy :: Abd Alla MDA; Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt. .
Dawood RM; Department of Microbial Biotechnology, National Research Center, Cairo, Egypt.
Rashed HAE; Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Farrag G; Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Ammar IAE; Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Mahmoud MMA; Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Salum GM; Department of Microbial Biotechnology, National Research Center, Cairo, Egypt.
Altanbouly AMA; Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
El Meguid MA; Department of Microbial Biotechnology, National Research Center, Cairo, Egypt.
Awady MKE; Department of Microbial Biotechnology, National Research Center, Cairo, Egypt.; Pokaż więcej
Źródło :: Archives of virology [Arch Virol] 2021 Apr; Vol. 166 (4), pp. 1071-1081. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :: Journal Article
MeSH Terms :: Antiviral Agents/*therapeutic use
Hepacivirus/*drug effects
Hepatitis C, Chronic/*drug therapy
RNA, Viral/*drug effects
Ribavirin/*therapeutic use
Adult ; Carbamates/therapeutic use ; Drug Therapy, Combination ; Female ; Hepacivirus/genetics ; Hepatitis C, Chronic/pathology ; Hepatitis C, Chronic/virology ; Humans ; Imidazoles/therapeutic use ; Leukocytes, Mononuclear/drug effects ; Leukocytes, Mononuclear/virology ; Liver/drug effects ; Liver/pathology ; Male ; Middle Aged ; Parenchymal Tissue/drug effects ; Parenchymal Tissue/pathology ; Pyrrolidines/therapeutic use ; RNA, Viral/analysis ; Secondary Prevention ; Sofosbuvir/therapeutic use ; Treatment Outcome ; Valine/analogs & derivatives ; Valine/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma.
Autorzy :: Sohn W; Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.; Pokaż więcej
Źródło :: The Korean journal of internal medicine [Korean J Intern Med] 2021 Mar; Vol. 36 (2), pp. 286-287. Date of Electronic Publication: 2021 Feb 25.
Typ publikacji :: Editorial; Comment
MeSH Terms :: Carcinoma, Hepatocellular*/drug therapy
Hepatitis C, Chronic*/complications
Hepatitis C, Chronic*/diagnosis
Hepatitis C, Chronic*/drug therapy
Liver Neoplasms*/drug therapy
Antiviral Agents/adverse effects ; Humans ; Sustained Virologic Response
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries].
Autorzy :: Simon KG; MVZ Dres. Eisenbach, Simon, Schwarz GbR, Leverkusen.
Serfert Y; Leberstiftungs-GmbH Deutschland, Hannover.
Buggisch P; ifi-Institut für interdisziplinäre Medizin, Hamburg.
Mauss S; Center for HIV and Hepatogastroenterology, Düsseldorf.
Boeker KHW; Leberzentrum, Hannover.
Klinker H; Universitätsklinikum Würzburg, Würzburg.
Müller T; Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin.
Merle U; Universitätsklinikum Heidelberg, Heidelberg.
Hüppe D; Gastroenterologische Gemeinschaftspraxis Herne, Herne.
Manns MP; Medizinische Hochschule Hannover, Hannover.
Wedemeyer H; Leberstiftungs-GmbH Deutschland, Hannover.; Medizinische Hochschule Hannover, Hannover.; Universitätsklinikum Essen, Universität Duisburg-Essen, Essen.; Pokaż więcej
Transliterated Title :: Veränderungen der Hepatitis-C-Virus-Genotyp-1a/1b-Verteilung zwischen 2004 und 2018 in Deutschland – eine Analyse von 17093 Patienten aus verschiedenen Real-World-Registern.
Źródło :: Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2021 Mar; Vol. 59 (3), pp. 241-249. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :: Journal Article
MeSH Terms :: Registries*
Hepacivirus/*genetics
Hepatitis C, Chronic/*epidemiology
Antiviral Agents/therapeutic use ; Drug Therapy, Combination ; Europe ; Female ; Genotype ; Germany/epidemiology ; Hepacivirus/classification ; Hepacivirus/isolation & purification ; Hepatitis C/diagnosis ; Hepatitis C/drug therapy ; Hepatitis C/epidemiology ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Humans ; Male
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: [From treatable to curable to eliminated ---- a decade of research progress in the diagnosis and treatment of hepatitis C].
Autorzy :: Rao HY; Peking University People's Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, China.
Wei L; Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.; Pokaż więcej
Źródło :: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology [Zhonghua Gan Zang Bing Za Zhi] 2021 Feb 20; Vol. 29 (2), pp. 102-107.
Typ publikacji :: Journal Article
MeSH Terms :: Hepatitis C*/drug therapy
Hepatitis C, Chronic*/diagnosis
Hepatitis C, Chronic*/drug therapy
Hepatitis C, Chronic*/epidemiology
Hepatitis, Viral, Human*
Antiviral Agents/therapeutic use ; China ; Hepacivirus/genetics ; Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.
Autorzy :: Makhlouf NA; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Abdelmalek MO; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Ibrahim ME; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Abu-Faddan NH; Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.
Kheila AE; Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Mahmoud AA; Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.; Pokaż więcej
Źródło :: Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2021 Feb 13; Vol. 10 (1), pp. 7-13.
Typ publikacji :: Journal Article
MeSH Terms :: Antiviral Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Fluorenes/*therapeutic use
Hematologic Diseases/*complications
Hepacivirus/*genetics
Hepatitis C, Chronic/*drug therapy
Liver/*pathology
Sofosbuvir/*therapeutic use
Adolescent ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Drug Therapy, Combination ; Elasticity Imaging Techniques ; Female ; Fluorenes/administration & dosage ; Fluorenes/adverse effects ; Hepacivirus/drug effects ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/pathology ; Hepatitis C, Chronic/virology ; Humans ; Liver/drug effects ; Male ; Sofosbuvir/administration & dosage ; Sofosbuvir/adverse effects ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection.
Autorzy :: Page K; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Melia MT; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Veenhuis RT; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Winter M; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Rousseau KE; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Massaccesi G; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Osburn WO; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Forman M; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Thomas E; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Thornton K; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Wagner K; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Vassilev V; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Lin L; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Lum PJ; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Giudice LC; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Stein E; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Asher A; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Chang S; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Gorman R; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Ghany MG; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Liang TJ; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Wierzbicki MR; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Scarselli E; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Nicosia A; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Folgori A; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Capone S; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.
Cox AL; From the University of New Mexico, Albuquerque (K.P., E.T., K.T., K.W.); Johns Hopkins University, Baltimore (M.T.M., R.T.V., M.W., K.E.R., G.M., W.O.O., M.F., A.L.C.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (S. Chang, R.G.), and the Emmes Company (M.R.W.), Rockville, and the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (M.G.G., T.J.L.) - all in Maryland; GSK Vaccines, Rixensart, Belgium (V.V., L.L.); the University of California, San Francisco, San Francisco (P.J.L., L.C.G., E. Stein, A.A.); the Centers for Disease Control and Prevention, Office of Policy, Planning, and Partnerships, Atlanta (A.A.); and ReiThera, Rome (E. Scarselli, A.F., S. Capone), and CEINGE, Naples (A.N.) - both in Italy.; Pokaż więcej
Źródło :: The New England journal of medicine [N Engl J Med] 2021 Feb 11; Vol. 384 (6), pp. 541-549.
Typ publikacji :: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :: Immunogenicity, Vaccine*
Hepatitis C Antibodies/*blood
Hepatitis C, Chronic/*prevention & control
Viral Hepatitis Vaccines/*immunology
Adenoviruses, Simian/genetics ; Adolescent ; Adult ; Animals ; Double-Blind Method ; Female ; Genetic Vectors ; Hepatitis C, Chronic/epidemiology ; Hepatitis C, Chronic/immunology ; Humans ; Incidence ; Male ; Middle Aged ; Pan troglodytes ; Substance Abuse, Intravenous ; T-Lymphocytes/immunology ; Vaccines, Synthetic/immunology ; Viral Hepatitis Vaccines/adverse effects ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study.
Autorzy :: Smit C; Stichting HIV Monitoring, Amsterdam, Netherlands.
Boyd A; Stichting HIV Monitoring, Amsterdam, Netherlands; Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, Netherlands. Electronic address: a.c..
Rijnders BJA; Department of Internal Medicine, Section Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
van de Laar TJW; Department of Donor Medicine Research, Laboratory of Blood-borne Infections, Sanquin Research and Laboratory of Medical Microbiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
Leyten EM; Department of Internal Medicine and Infectious Diseases, Medical Centre Haaglanden, Den Haag, Netherlands.
Bierman WF; University of Groningen, Department of Internal Medicine, Section Infectious Diseases, University Medical Centre Groningen, Groningen, Netherlands.
Brinkman K; Department of Internal Medicine and Infectious Diseases, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
Claassen MAA; Department of Internal Medicine and Infectious Diseases, Rijnstate Ziekenhuis, Arnhem, Netherlands.
den Hollander J; Department of Internal Medicine and Infectious Diseases, Maasstad Ziekenhuis, Rotterdam, Netherlands.
Boerekamps A; Department of Internal Medicine, Section Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Newsum AM; Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, Netherlands; Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Schinkel J; Department of Medical Microbiology, Section of Clinical Virology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Prins M; Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, Netherlands; Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Arends JE; Department of Internal Medicine and Infectious Diseases, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands.
Op de Coul ELM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
van der Valk M; Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Reiss P; Stichting HIV Monitoring, Amsterdam, Netherlands; Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.; Pokaż więcej
Corporate Authors :: ATHENA observational cohort
Źródło :: The lancet. HIV [Lancet HIV] 2021 Feb; Vol. 8 (2), pp. e96-e105. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antiviral Agents/*therapeutic use
HIV Infections/*epidemiology
HIV-1/*drug effects
Hepacivirus/*drug effects
Hepatitis C, Chronic/*epidemiology
Substance Abuse, Intravenous/*epidemiology
Adult ; Coinfection ; Female ; HIV Infections/drug therapy ; HIV Infections/virology ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/prevention & control ; Hepatitis C, Chronic/virology ; Homosexuality, Male ; Humans ; Incidence ; Male ; Middle Aged ; Netherlands/epidemiology ; Retrospective Studies ; Substance Abuse, Intravenous/virology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Multiple Tumor-Like Fatty Changes in the Liver Disappeared After Hepatitis C Virus Eradication With Direct-Acting Antiviral Treatment.
Autorzy :: Sakai N; Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Chuo-Ku, Niigata, Japan.
Kamimura K
Terai S; Pokaż więcej
Źródło :: The American journal of gastroenterology [Am J Gastroenterol] 2021 Feb 01; Vol. 116 (2), pp. 237.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Antiviral Agents/*therapeutic use
Fatty Liver/*diagnostic imaging
Hepatitis C, Chronic/*drug therapy
Fatty Liver/etiology ; Fatty Liver/pathology ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/diagnostic imaging ; Hepatitis C, Chronic/pathology ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Memory-like HCV-specific CD8 T cells retain a molecular scar after cure of chronic HCV infection.
Autorzy :: Hensel N; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Faculty of Biology, University of Freiburg, Freiburg, Germany.
Gu Z; Heidelberg Center for Personalised Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sagar; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Wieland D; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Jechow K; Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Digital Health Center, Berlin, Germany.
Kemming J; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Faculty of Biology, University of Freiburg, Freiburg, Germany.
Llewellyn-Lacey S; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Gostick E; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Sogukpinar O; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Emmerich F; Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Institute for Transfusion Medicine and Gene Therapy, University Medical Center, University of Freiburg, Freiburg, Germany.
Price DA; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.; Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.
Bengsch B; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Boettler T; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Neumann-Haefelin C; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Eils R; Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Digital Health Center, Berlin, Germany.; Health Data Science Unit, Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
Conrad C; Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Digital Health Center, Berlin, Germany.
Bartenschlager R; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.; Division Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany.; German Center for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany.
Grün D; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Ishaque N; Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Digital Health Center, Berlin, Germany.
Thimme R; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany. .; Faculty of Medicine, University of Freiburg, Freiburg, Germany. .
Hofmann M; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany. .; Faculty of Medicine, University of Freiburg, Freiburg, Germany. .; Pokaż więcej
Źródło :: Nature immunology [Nat Immunol] 2021 Feb; Vol. 22 (2), pp. 229-239. Date of Electronic Publication: 2021 Jan 04.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Transcriptome*
CD8-Positive T-Lymphocytes/*immunology
Hepacivirus/*immunology
Hepatitis C, Chronic/*immunology
Immunologic Memory/*genetics
Antigens, Viral/immunology ; Antiviral Agents/therapeutic use ; CD8-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/virology ; Gene Expression Profiling ; Gene Regulatory Networks ; Hepacivirus/drug effects ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/genetics ; Hepatitis C, Chronic/virology ; Host-Pathogen Interactions ; Humans ; Phenotype ; Remission Induction ; Single-Cell Analysis ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
Autorzy :: Nozaki A; Gastroenterological Center, Yokohama City University Medical Center.
Chuma M; Gastroenterological Center, Yokohama City University Medical Center.
Hara K; Gastroenterological Center, Yokohama City University Medical Center.
Moriya S; Gastroenterological Center, Yokohama City University Medical Center.
Fukuda H; Gastroenterological Center, Yokohama City University Medical Center.
Numata K; Gastroenterological Center, Yokohama City University Medical Center.
Tanaka K; Gastroenterological Center, Yokohama City University Medical Center.
Morimoto M; Department of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center.
Sakamaki K; Center for Data Science.
Yamanaka T; Department of Biostatistics, School of Medicine, Yokohama City University.
Kondo M; Department of Gastroenterology, Yokohama City University Graduate School of Medicine.
Maeda S; Department of Gastroenterology, Yokohama City University Graduate School of Medicine.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2021 Mar 26; Vol. 100 (12), pp. e25110.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Benzimidazoles/*administration & dosage
Fluorenes/*administration & dosage
Hepacivirus/*drug effects
Hepatitis C, Chronic/*drug therapy
Liver Cirrhosis/*drug therapy
Ribavirin/*administration & dosage
Sofosbuvir/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Drug Therapy, Combination ; Female ; Hepatitis C, Chronic/complications ; Humans ; Liver/drug effects ; Liver/virology ; Liver Cirrhosis/virology ; Male ; Middle Aged ; Prospective Studies ; Sustained Virologic Response ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis.
Autorzy :: Kamimura H; Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan .
Kamimura K; Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Tsuchiya A; Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Terai S; Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.; Pokaż więcej
Źródło :: BMJ case reports [BMJ Case Rep] 2021 Mar 25; Vol. 14 (3). Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Coinfection/*therapy
Coinfection/*virology
Hepatitis C, Chronic/*therapy
Hepatitis, Autoimmune/*therapy
Plasmapheresis/*methods
Antiviral Agents/therapeutic use ; COVID-19/complications ; COVID-19/therapy ; Drug Therapy, Combination ; Female ; Hepatitis C, Chronic/complications ; Hepatitis, Autoimmune/complications ; Humans ; Interferon alpha-2/therapeutic use ; Middle Aged ; Polyethylene Glycols/therapeutic use ; Positive-Strand RNA Viruses/isolation & purification ; Ribavirin/therapeutic use ; SARS-CoV-2 ; Treatment Outcome ; Viral Load
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Impact of acute kidney injury on survival in patients with chronic hepatitis C: a retrospective cohort study.
Autorzy :: Jeon H; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongnam, 51472, Republic of Korea.
Kim JH; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongnam, 51472, Republic of Korea.
Lee SS; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea. .; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongnam, 51472, Republic of Korea. .; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea. .
Kim HJ; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongnam, 51472, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Cha RR; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongnam, 51472, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Cho HC; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Lee JM; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongnam, 51472, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Ha CY; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Kim HJ; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon-si, Gyeongnam, 51472, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Kim TH; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Jung WT; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Lee OJ; Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Republic of Korea.; Pokaż więcej
Źródło :: BMC infectious diseases [BMC Infect Dis] 2021 Mar 25; Vol. 21 (1), pp. 301. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :: Journal Article
MeSH Terms :: Acute Kidney Injury/*pathology
Hepatitis C, Chronic/*pathology
Acute Kidney Injury/complications ; Acute Kidney Injury/epidemiology ; Acute Kidney Injury/mortality ; Aged ; Female ; Follow-Up Studies ; Hepatitis C, Chronic/complications ; Humans ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multivariate Analysis ; Retrospective Studies ; Risk Factors
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 14 14.

Tytuł :: Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.
Autorzy :: Gomaa A; National Liver Institute, Menoufia University, Shebeen El-Kom, Egypt.
Allam N; National Liver Institute, Menoufia University, Shebeen El-Kom, Egypt.
Waked I; National Liver Institute, Menoufia University, Shebeen El-Kom, Egypt. .; Pokaż więcej
Źródło :: Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2021 Mar; Vol. 57 (3), pp. 199-208.
Typ publikacji :: Journal Article
MeSH Terms :: Hepatitis C*/drug therapy
Hepatitis C, Chronic*/drug therapy
Antiviral Agents/adverse effects ; Benzimidazoles/adverse effects ; Drug Resistance, Viral/genetics ; Genotype ; Hepacivirus/genetics ; Humans ; Valine/analogs & derivatives ; Viral Nonstructural Proteins
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
Autorzy :: Chiu HC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chiu YC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yang EH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chang TT; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chien SC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wu IC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wu CH; Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
Cheng PN; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: .; Pokaż więcej
Źródło :: Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2021 Mar; Vol. 120 (3), pp. 983-990. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :: Journal Article
MeSH Terms :: Hepatitis C, Chronic*/drug therapy
Antiviral Agents/adverse effects ; Benzimidazoles ; Drug Therapy, Combination ; Fluorenes ; Genotype ; Hepacivirus/genetics ; Humans ; Ribavirin/therapeutic use ; Sofosbuvir/adverse effects ; Taiwan ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
Autorzy :: Hsu SJ; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; Hepatology Medical Center, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan. Electronic address: .
Yu ML; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: .
Su CW; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Electronic address: .
Peng CY; Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan. Electronic address: .
Chien RN; Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taiwan. Electronic address: .
Lin HH; Division of Gastroenterology and Hepatology, Taipei Tzu Chi Hospital, Taipei, Taiwan. Electronic address: .
Lo GH; Division of Gastroenterology, Department of Medical Research, E-DA Hospital, Kaohsiung, Taiwan. Electronic address: .
Su WW; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan. Electronic address: .
Kuo HT; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. Electronic address: .
Hsu CW; Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taiwan. Electronic address: .
Yang SS; Liver Center, Cathay General Hospital Medical Center, Taipei, Taiwan. Electronic address: .
Yang SS; Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Electronic address: .
Tseng KC; PharmaEssentia Corp., Taipei, Taiwan. Electronic address: .
Qin A; PharmaEssentia Corp., Taipei, Taiwan. Electronic address: .
Huang YW; Liver Center, Cathay General Hospital Medical Center, Taipei, Taiwan; PharmaEssentia Corp., Taipei, Taiwan; School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address: .
Chuang WL; Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: .; Pokaż więcej
Źródło :: Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2021 Mar; Vol. 120 (3), pp. 956-964. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji :: Journal Article; Randomized Controlled Trial
MeSH Terms :: Hepatitis C, Chronic*/drug therapy
Antiviral Agents/adverse effects ; Drug Therapy, Combination ; Genotype ; Hepacivirus/genetics ; Humans ; Polyethylene Glycols/therapeutic use ; Recombinant Proteins/therapeutic use ; Ribavirin/therapeutic use ; Taiwan
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach.
Autorzy :: Kamali I; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda. .
Barnhart DA; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.; Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA.
Nyirahabihirwe F; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
de la Paix Gakuru J; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Uwase M; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Nizeyumuremyi E; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Walker S; GlaxoSmithKline, Philadelphia, PA, USA.
Mazimpaka C; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
de Dieu Gatete J; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Makuza JD; Rwanda Biomedical Centre, IHDPC, Kigali, Rwanda.; School of Population and Public Health, University of British Columbia, Vancouver, Canada.
Serumondo J; Rwanda Biomedical Centre, IHDPC, Kigali, Rwanda.
Kateera F; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
d'Amour Ndahimana J; Partners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.; Pokaż więcej
Źródło :: BMC infectious diseases [BMC Infect Dis] 2021 Feb 25; Vol. 21 (1), pp. 220. Date of Electronic Publication: 2021 Feb 25.
Typ publikacji :: Journal Article
MeSH Terms :: Antiviral Agents/*therapeutic use
Hepatitis C, Chronic/*drug therapy
Mobile Health Units/*statistics & numerical data
Rural Health/*statistics & numerical data
Aged ; Female ; Hepacivirus/isolation & purification ; Hepatitis C, Chronic/diagnosis ; Humans ; Male ; Mass Screening ; Middle Aged ; Mobile Health Units/economics ; Mobile Health Units/organization & administration ; Rural Health/economics ; Rwanda/epidemiology
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 18 18.

Tytuł :: [Neurological complications of hepatitis C infections].
Autorzy :: Kleefeld F; Klinik für Neurologie, Universitätsmedizin Charité, Charitéplatz 1, 10117, Berlin, Deutschland.
Arendt G; Neurologie, Neuro-Centrum Düsseldorf, Hohenzollernstr. 5, 40211, Düsseldorf, Deutschland.
Neuen-Jacob E; Institut für Neuropathologie, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland.
Maschke M; Klinik für Neurologie, Krankenhaus der Barmherzigen Brüder, Nordallee 1, 54292, Trier, Deutschland.
Husstedt I; Praxis an der Klinik Maria Frieden, Am Krankenhaus 1, 48291, Telgte/Münster, Deutschland.
Obermann M; Klinik für Neurologie, Asklepios Kliniken Schildautal, Karl-Herold-Str. 1, 38723, Seesen, Deutschland.
Schmidt H; Klinik für Neurologie, Elbe-Kliniken Stade, Bremervörder Str. 111, 21682, Stade, Deutschland.
Hahn K; Klinik für Neurologie, Universitätsmedizin Charité, Charitéplatz 1, 10117, Berlin, Deutschland. .; Pokaż więcej
Transliterated Title :: Neurologische Komplikationen der Hepatitis-C-Infektion.
Corporate Authors :: Deutsche Gesellschaft für Neuro-AIDS und Neuro-Infektiologie (DGNANI)
Źródło :: Der Nervenarzt [Nervenarzt] 2021 Feb; Vol. 92 (2), pp. 144-149. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antiviral Agents*/therapeutic use
Cryoglobulinemia*/drug therapy
Hepatitis C*/complications
Hepatitis C*/diagnosis
Hepatitis C*/drug therapy
Hepatitis C, Chronic*/drug therapy
Hepacivirus ; Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Micro-elimination of HIV and HCV co-infection.
Autorzy :: Dusheiko G; Liver Unit, Kings College Hospital, London, UK. Electronic address: .
Childs K; Sexual Health and HIV Unit, Kings College Hospital, London, UK.; Pokaż więcej
Źródło :: The lancet. HIV [Lancet HIV] 2021 Feb; Vol. 8 (2), pp. e61-e62. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :: Journal Article; Comment
MeSH Terms :: Antiviral Agents*/therapeutic use
Coinfection*/drug therapy
HIV Infections*/complications
HIV Infections*/epidemiology
HIV Infections*/prevention & control
Hepatitis C*/complications
Hepatitis C*/epidemiology
Hepatitis C*/prevention & control
Hepatitis C, Chronic*/drug therapy
Humans ; Netherlands ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: High Prevalence of New-Onset or Worsening Hepatitis C Virus-Related Musculoskeletal Symptoms After Beginning Direct-Acting Antiviral Therapy: A Challenging Novel Observation.
Autorzy :: Haroon M; Fatima Memorial Hospital FMH College of Medicine and Dentistry.
Anis K; Pakistan Kidney and Liver Institute, Lahore, Pakistan.
Khan Z; Pakistan Kidney and Liver Institute, Lahore, Pakistan.
Nawaz N; Pakistan Kidney and Liver Institute, Lahore, Pakistan.; Pokaż więcej
Źródło :: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2021 Feb; Vol. 73 (2), pp. 355-356. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :: Letter
MeSH Terms :: Antiviral Agents/*therapeutic use
Arthritis, Rheumatoid/*physiopathology
Fibromyalgia/*physiopathology
Hepatitis C, Chronic/*drug therapy
Adult ; Arthritis/epidemiology ; Arthritis/physiopathology ; Arthritis, Rheumatoid/epidemiology ; Female ; Fibromyalgia/epidemiology ; Hepatitis C, Chronic/epidemiology ; Humans ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Symptom Flare Up
: Opinia redakcyjna

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Hepatitis C, Chronic"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język